Prof. PeptideProf. Peptide
Guide

CJC-1295 Dosage in 2026: With and Without DAC

CJC-1295 is a lab-made analogue of growth hormone-releasing hormone sold in two forms, with and without DAC. Clinics give the no-DAC form at 100 to 300 mcg one to three times a day and the DAC form at 1,000 to 2,000 mcg (1 to 2 mg) once or twice a week [9][12]; every human study used the DAC form [1][5]. It is not FDA-approved.

Two molecules, one name

The DAC form binds albumin and lasts days; the no-DAC form (Mod GRF 1-29) lasts minutes and is dosed daily. A dose figure means nothing without the form it belongs to [1][9].

How is CJC-1295 dosed?

No trial has set a CJC-1295 dose. Clinics commonly prescribe the no-DAC form at 100 to 300 mcg by subcutaneous injection, one to three times a day, and the DAC form once or twice a week at 1,000 to 2,000 mcg (1 to 2 mg) a dose [9][11][12][13][14]. These are clinic practices, not tested protocols.

The clinics below are representative of the clinic pages read for CJC-1295 alone; each row is that clinic's own published protocol, with the form it names.

ClinicForm and routeDoseSchedule
Pru [9]No-DAC and DAC; subcutaneousNo-DAC 100–300 mcg per dose; DAC 1,000–2,000 mcg (1–2 mg) per doseNo-DAC one to three times a day; DAC once or twice a week
Live Vital [11]Both forms named; subcutaneousNot statedOne to two times a day; 8–12-week cycles with breaks
Sante Clinics [12]Both forms; subcutaneousNot statedNo-DAC daily; DAC once or twice a week
Azani Medical Spa [13]Form not stated; subcutaneous300 mcg a dayDaily, on an empty stomach
NAVA Center [14]DAC; subcutaneousNot statedOne injection a week
  • Range reported: 100 to 300 mcg a dose for the no-DAC form; 1,000 to 2,000 mcg (1 to 2 mg) a dose for the DAC form, once or twice a week [9][13].
  • Course: one clinic runs 8- to 12-week cycles with breaks [11]; the others publish no course length.
  • One clinic writes that the figures come from research and clinic protocols, not an approved label, and that dosing the DAC form above roughly 2,000 mcg (2 mg) a week is generally discouraged, a statement it gives without a study [9].
  • Count: of the eight largest peptide telehealth companies, one publishes CJC-1295 dosing [9]; of 5 clinic pages read for CJC-1295 alone, 2 give an amount; 88 clinics in Prof. Peptide's clinic registry list it.

Clinic cautions are under What are the side effects of CJC-1295?, its status under Is CJC-1295 legal?, and the trial doses under What do human studies show about CJC-1295 dosing? The CJC-1295 and ipamorelin pairing is covered in how often CJC-1295 and ipamorelin are dosed.

How is CJC-1295 taken?

Clinics administer CJC-1295 by subcutaneous injection: the no-DAC form daily, the DAC form once or twice a week [9][12][14]. One clinic gives it on an empty stomach, an hour before or two hours after a meal [13]. Its human studies gave the DAC form by subcutaneous injection, with a half-life of 5.8 to 8.1 days [1][2][5].

No approved label sets out a route or storage. The peptide calculator does the vial arithmetic; it does not set a dose.

What are the side effects of CJC-1295?

CJC-1295's most common side effect in its trials was injection-site reactions; FDA's review of the full papers also lists headache (63% vs 14% on placebo in one study), diarrhea, flushing with warmth and low blood pressure (30%), and a dose-related rise in heart rate [1][5]. Most effects were more common at 125 or 250 mcg/kg [5].

  • HIV trial (unpublished): one participant had chest discomfort two hours after an 11th weekly dose, an ECG confirmed a heart attack, and the participant died about an hour later; the attending clinician attributed it to pre-existing coronary artery disease, and the trial was stopped [5].
  • Also reported: transient leg muscle contractions and loss of coordination in one subject, and dizziness with low blood pressure in two [5]. FDA's safety-risk entry cites serious adverse events including increased heart rate and systemic vasodilatory reaction [4].

What clinics report

Clinics list injection-site reactions, water retention, flushing, headache, tingling or numbness and increased hunger, and one says these are more common with the DAC form [9][10][11][12]. One clinic avoids it in active cancer, pregnancy or breastfeeding, diabetic retinopathy, pituitary tumors and uncontrolled diabetes [11].

What do human studies show about CJC-1295 dosing?

CJC-1295's human evidence is 63 healthy adults across three studies, including two randomized, placebo-controlled, double-blind trials, all of the DAC form and all measuring hormones, not health outcomes [1][2][3][5]. A phase 2 trial in 192 people with HIV-associated fat gain was stopped after a death and never published [5].

  • Doses: the trials dosed by body weight, single, weekly or every-other-week subcutaneous doses of 30 to 250 mcg/kg, with 30 or 60 mcg/kg judged best tolerated; the HIV trial used weekly doses of 60 to 240 mcg/kg [1][5]. These are trial doses, not recommendations.
  • Teichman et al. 2006: two ascending-dose randomized trials of 28 and 49 days; half-life 5.8 to 8.1 days; no serious adverse reactions [1].
  • Ionescu and Frohman 2006: 60 or 90 mcg/kg once in healthy men; growth hormone pulses preserved and trough levels up 7.5-fold [2].
  • Sackmann-Sala et al. 2009: blood-protein changes in 11 men one week after a dose [3].

FAQ

What is the dosage of CJC-1295?
No trial has set one. Clinics commonly give the no-DAC form at 100 to 300 mcg by subcutaneous injection one to three times a day, and the DAC form at 1,000 to 2,000 mcg (1 to 2 mg) once or twice a week. The human trials, all of the DAC form, dosed by body weight, 30 to 250 mcg/kg.
What is the difference between CJC-1295 with and without DAC?
DAC (drug affinity complex) lets the molecule bind to albumin in the blood, so the DAC form lasts days and is given once or twice a week, while the no-DAC form, also sold as Mod GRF 1-29, is given daily. Every published human study used the DAC form; its half-life was 5.8 to 8.1 days.
How often is CJC-1295 dosed?
Clinics give the no-DAC form daily, one to three times a day, and the DAC form once or twice a week. One clinic runs 8- to 12-week cycles with breaks. In the DAC trials, doses were given once, weekly or every other week, with a half-life of 5.8 to 8.1 days.
What are the side effects of CJC-1295?
In its trials the most common was injection-site reactions; FDA's review also lists headache (63% vs 14% on placebo in one study), diarrhea, flushing and low blood pressure, and a dose-related rise in heart rate. Clinics list water retention, flushing, headache, tingling or numbness and increased hunger, more often with the DAC form.
Is CJC-1295 legal?
CJC-1295 is not FDA-approved. FDA lists it as nominated but withdrawn from Category 2, and its advisory committee voted in December 2024, 0 in favor and 13 against, on placing CJC-1295 or any DAC form on the 503A compounding list. WADA prohibits it in sport under S2.2.4.

References

  1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
  3. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009. PMID 19386527. https://pubmed.ncbi.nlm.nih.gov/19386527/
  4. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026; read November 3, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. U.S. Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: CJC-1295-related bulk drug substances. Read November 3, 2026. https://www.fda.gov/media/183819/download
  6. World Anti-Doping Agency. The Prohibited List (2026), S2.2.4. Valid January 1, 2026. https://www.wada-ama.org/en/prohibited-list
  7. U.S. Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Approved February 21, 2025. https://www.fda.gov/media/185642/download
  8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, July 23–24, 2026: final agenda (seven substances; CJC-1295 is not among them). Read November 5, 2026. https://www.fda.gov/media/193771/download
  9. Pru, CJC-1295 dosage, updated July 9, 2026; read November 5, 2026. Cited for its stated doses for each form, its side effects and its DAC note. https://joinpru.com/blog/cjc-1295-dosage
  10. Pru, CJC-1295 guide, updated July 9, 2026; read November 5, 2026. Cited for its side-effect list and its status account. https://joinpru.com/blog/cjc-1295-guide
  11. Patrick Taylor, MD (Live Vital; drpattaylor.com). Read November 5, 2026. Cited for its own schedule, cycle, side effects and contraindications. https://www.drpattaylor.com/peptides/cjc-1295
  12. Sante Clinics, CJC-1295 peptide: benefits, science and uses. Read November 5, 2026. Cited for its route and schedule for each form and its side-effect list. https://santeclinics.com/blog/cjc-1295-peptide-benefits-science-uses
  13. Azani Medical Spa, Bethlehem, Pennsylvania. Read November 5, 2026. Cited for its own dose and timing. https://azanimedicalspa.com/peptides-at-azani-medical-spa/
  14. NAVA Center, muscle and strength peptide therapy. Read November 5, 2026. Cited for its weekly schedule for CJC-1295 with DAC. https://navacenter.com/services/muscle-strength-peptide-therapy/

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated